Our Approach

Accelerate regenerative medicine development by leveraging naturally existing genetic pathways in the human trophoblast stem cell

intellectual property

We have 54 granted patents and 46 pending patents globally relating to human trophoblast stem cell. We also have developed proprietary know-how to culture and differentiate the hTSC.  

54
Patents Granted
46
Patents In Process
7
Patent Families

GMP & CMC

Ensuring our cell therapy products meet the highest standards of Good Manufacturing Practice (GMP) and Chemistry, Manufacturing, and Controls (CMC) is essential to delivering safe and effective therapies.  

With Theragent overseeing our GMP & CMC processes, we rigorously control our manufacturing to ensure consistent product quality, while our collaboration with Darkhorse Consulting ensures comprehensive compliance with all regulatory requirements. 

For cell therapies, where complex biological processes are involved, strict adherence to GMP and CMC is crucial, as even minor deviations can impact patient safety and efficacy. 

Ensuring our cell therapy products meet the highest standards of Good Manufacturing Practice (GMP) and Chemistry, Manufacturing, and Controls (CMC) is essential to delivering safe and effective therapies.  

‍

Accelerate Regenerative Medicine Development

Explore how our starting materials and genetically engineered platforms can help accelerate your regenerative medicine product time to market.

Explore our platforms

press releases

Learn about our exciting work with leading biopharma companies and research institutions.  

Connect with us to learn more about our hTSC and derived platforms

We are ready to share our hTSCs with you to help you accelerate your research and product development.

Partner with Us